Ken Griffin Candel Therapeutics, Inc. Put Options Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
Put Options
1 transactions
Others Institutions Holding CADL
# of Institutions
53Shares Held
6.02MCall Options Held
82.9KPut Options Held
56K-
Northpond Ventures, LLC1.94MShares$9.35 Million41.58% of portfolio
-
Black Rock Inc. New York, NY823KShares$3.98 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA819KShares$3.95 Million0.0% of portfolio
-
State Street Corp Boston, MA473KShares$2.28 Million0.0% of portfolio
-
Sands Capital Ventures, LLC Arlington, VA406KShares$1.96 Million1.27% of portfolio
About Candel Therapeutics, Inc.
- Ticker CADL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,891,900
- Market Cap $140M
- Description
- Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...